Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Volume 5, Issue 4, Pages 877-886Publisher
ELSEVIER
DOI: 10.1016/j.jaip.2017.04.027
Keywords
Biologic therapy; Comorbidities; Adherence; Inhaled corticosteroid; Phenotype; Severe asthma
Categories
Funding
- National Institutes of Health
- Aimmune
- AstraZeneca
- Chiesi
- Sanofi
- Teva Pharmaceuticals
- FDA long-acting b-agonist Trials Joint Data Safety Monitoring Board
Ask authors/readers for more resources
Severe asthma is associated with significant morbidity and can be challenging to assess and control, due to heterogeneity of disease, complexity of diagnosis, and impact of comorbidities. A structured approach to the assessment and management of severe asthma may be helpful to the practicing clinician. First, it is important to confirm a diagnosis of asthma. In patients who are either not responding to treatment, or who require high doses of medication to control symptoms, it is highly possible that disease mimickers or comorbidities are present and can inhibit therapeutic responsiveness. The assessment and management of common comorbidities of asthma may dramatically impact disease control and thus medication requirement. Determining medication adherence and optimizing drug dose and delivery may separate out truly severe asthmatics from those not using medications regularly or properly. Next, although true personalized medicine for severe asthma is not yet realized, for those individuals with severe asthma, phenotypic characteristics of each patient may guide which therapeutic options may be most effective for that patient. Finally, evaluation and management of severe asthma at a referral center can add additional phenotyping, therapeutic, and diagnostic strategies. (C) 2017 American Academy of Allergy, Asthma & Immunology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available